A New Approach to Cardiac Risk Assessment

The current strategy for evaluating cardiac risk, which focuses on QT interval prolongation and hERG inhibition, has proven to be highly successful in eliminating preclinical candidates with cardiac toxicity. However, these assays are overly sensitive and lack specificity, potentially limiting development pipelines and increasing costs in drug development. Termination of drug discovery programs is often attributed to cardiac toxicity, with up to 60% of drug candidates showing potential cardiac repolarization liability. By placing greater emphasis on the accurate prediction of proarrhythmic drug effects early in development, the Comprehensive in vitro Proarrhythmia Assay (CiPA) initiative is expected to reduce unwarranted drug discovery attrition, improve accuracy in predicting cardiac risk, and ultimately make better, safer drugs to benefit doctors and patients.

Access the CiPA Guide to learn more about this initiative and how to apply these principles to your discovery program.